Recruiting NCT07492927
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Clinically Significant Prostate Cancer. Basic parameters: from 18 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Primary outcome measures
- The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing csPCa [Time frame: The time of prostate biopsy]
Secondary outcome measures (1)
- Diagnostic efficacy of plasma exo-RNA panel in diagnosing csPCa and its comparison with other imaging methods or blood tests [Time frame: The time of prostate biopsy]
Eligibility criteria
Inclusion criteria
- Blood prostate-specific antigen PSA>4ng/dl;
- Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
- The patient is willing to undergo prostate biopsy.
Exclusion criteria
- Previous diagnosis of prostate cancer through prostate biopsy;
- History of other malignant tumors in the past two years;
- According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 9 centers
- The First Hospital of Lanzhou University — Lanzhou
- General Hospital of Ningxia Medical University — Yinchuan
- Qinghai University Affiliated Hospital — Xining
- Weinan Central Hospital — Weinan
- Shaanxi Provincial People's Hospital — Xi'an
- Xijing 986 Hospital — Xi'an
- The Second Affiliated Hospital of Shaanxi University of Chinese Medicine — Xianyang
- Yan'an University Affiliated Hospital — Yan’an
- … and 1 more center
United States · 1 center
- Northwestern Memorial Hospital — Chicago
Identifiers
NCT: NCT07492927 · KY20262014-F-1